HGEN
Humanigen, Inc. [HGEN] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
HGEN Stock Summary
In the News
HGEN Financial details
HGEN Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0.01 | 0.06 | 0.04 | |
| Net income per share | -0.63 | -0.52 | -2.46 | -4.08 | -1.18 | |
| Operating cash flow per share | -0.33 | -0.18 | -1.89 | -3.14 | -1.29 | |
| Free cash flow per share | -0.33 | -0.18 | -1.89 | -3.14 | -1.29 | |
| Cash per share | 0.04 | 0.01 | 1.83 | 1.2 | 0.17 | |
| Book value per share | -0.43 | -0.64 | 1.23 | -0.4 | -0.79 | |
| Tangible book value per share | -0.43 | -0.64 | 1.23 | -0.4 | -0.79 | |
| Share holders equity per share | -0.43 | -0.64 | 1.23 | -0.4 | -0.79 | |
| Interest debt per share | 0.23 | 0.35 | 0.04 | 0.47 | 0.05 | |
| Market cap | 66.33M | 54.79M | 646.85M | 217.75M | 7.14M | |
| Enterprise value | 69.01M | 61.13M | 579.12M | 172.74M | -3.02M | |
| P/E ratio | -5.53 | -4.71 | -7.12 | -0.91 | -0.1 | |
| Price to sales ratio | 0 | 0 | 2.07K | 60.57 | 2.84 | |
| POCF ratio | -10.68 | -13.69 | -9.26 | -1.18 | -0.09 | |
| PFCF ratio | -10.68 | -13.69 | -9.26 | -1.18 | -0.09 | |
| P/B Ratio | -8.18 | -3.83 | 14.2 | -9.19 | -0.15 | |
| PTB ratio | -8.18 | -3.83 | 14.2 | -9.19 | -0.15 | |
| EV to sales | 0 | 0 | 1.86K | 48.05 | -1.2 | |
| Enterprise value over EBITDA | -6.28 | -6.83 | -6.57 | -0.74 | 0.04 | |
| EV to operating cash flow | -11.11 | -15.28 | -8.29 | -0.94 | 0.04 | |
| EV to free cash flow | -11.11 | -15.28 | -8.29 | -0.94 | 0.04 | |
| Earnings yield | -0.18 | -0.21 | -0.14 | -1.1 | -9.84 | |
| Free cash flow yield | -0.09 | -0.07 | -0.11 | -0.85 | -10.74 | |
| Debt to equity | -0.43 | -0.45 | 0 | -1.06 | 0 | |
| Debt to assets | 2.55 | 12.4 | 0 | 0.35 | 0 | |
| Net debt to EBITDA | -0.24 | -0.71 | 0.77 | 0.19 | 0.15 | |
| Current ratio | 0.16 | 0.03 | 3.34 | 1.03 | 0.2 | |
| Interest coverage | -13.3 | -6.63 | -66.02 | -102.81 | -23.41 | |
| Income quality | 0.52 | 0.39 | 0.78 | 0.78 | 1.08 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 50.63 | 6.47 | 6.21 | |
| Research and developement to revenue | 0 | 0 | 233.05 | 59.28 | 21.96 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | -0.06 | 0 | 0 | |
| Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 6.76 | 1.49 | 2.31 | |
| Graham number | 2.47 | 2.74 | 8.26 | 6.1 | 4.57 | |
| ROIC | 2.49 | 1.29 | -1.97 | -178.3 | 1.45 | |
| Return on tangible assets | -8.76 | -22.26 | -1.33 | -3.36 | -6.27 | |
| Graham Net | -0.46 | -0.66 | 1.22 | -0.42 | -0.8 | |
| Working capital | -6.96M | -13.14M | 47.8M | 2.25M | -45.09M | |
| Tangible asset value | -8.11M | -14.32M | 45.53M | -23.69M | -46.77M | |
| Net current asset value | -8.18M | -14.39M | 45.46M | -23.78M | -46.86M | |
| Invested capital | -0.43 | -0.45 | 0 | -1.06 | 0 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 3.09M | 3.95M | 9.06M | 28.89M | 42.61M | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0 | 0 | 0 | 0 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | 1.48 | 0.81 | -2 | 10.09 | 1.5 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-03-31 for Q1
| Metric | History | 2022-03-31 | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.02 | 0.01 | 0 | 0 | 0 | |
| Net income per share | -0.32 | -0.43 | -0.23 | 0.07 | -0.03 | |
| Operating cash flow per share | -0.3 | -0.36 | -0.17 | -0.24 | -0.06 | |
| Free cash flow per share | -0.3 | -0.36 | -0.17 | -0.24 | -0.06 | |
| Cash per share | 1.05 | 0.67 | 0.24 | 0.17 | 0.03 | |
| Book value per share | -0.38 | -0.71 | -0.52 | -0.79 | -0.42 | |
| Tangible book value per share | -0.38 | -0.71 | -0.52 | -0.79 | -0.42 | |
| Share holders equity per share | -0.38 | -0.71 | -0.52 | -0.79 | -0.42 | |
| Interest debt per share | 0.4 | 0.37 | 0.01 | 0 | 0 | |
| Market cap | 197.43M | 125.09M | 18.26M | 7.14M | 17.09M | |
| Enterprise value | 153.67M | 103.43M | -6.47M | -3.02M | 13.99M | |
| P/E ratio | -2.32 | -1.04 | -0.2 | 0.41 | -1.03 | |
| Price to sales ratio | 190.57 | 120.74 | 82.61 | 32.3 | 77.32 | |
| POCF ratio | -10.15 | -4.93 | -1.05 | -0.49 | -2.42 | |
| PFCF ratio | -10.15 | -4.93 | -1.05 | -0.49 | -2.42 | |
| P/B Ratio | -7.88 | -2.5 | -0.35 | -0.15 | -0.34 | |
| PTB ratio | -7.88 | -2.5 | -0.35 | -0.15 | -0.34 | |
| EV to sales | 148.33 | 99.83 | -29.27 | -13.65 | 63.31 | |
| Enterprise value over EBITDA | -7.48 | -3.52 | 0.29 | -0.67 | -3.36 | |
| EV to operating cash flow | -7.9 | -4.08 | 0.37 | 0.21 | -1.98 | |
| EV to free cash flow | -7.9 | -4.08 | 0.37 | 0.21 | -1.98 | |
| Earnings yield | -0.11 | -0.24 | -1.28 | 0.61 | -0.24 | |
| Free cash flow yield | -0.1 | -0.2 | -0.95 | -2.04 | -0.41 | |
| Debt to equity | -1.01 | -0.51 | 0 | 0 | 0 | |
| Debt to assets | 0.35 | 0.51 | 0 | 0 | 0 | |
| Net debt to EBITDA | 2.13 | 0.74 | 1.1 | -2.25 | 0.74 | |
| Current ratio | 1 | 0.64 | 0.34 | 0.2 | 0.09 | |
| Interest coverage | -27.97 | -38.22 | -17.5 | 36.42 | -235.28 | |
| Income quality | 0.91 | 0.84 | 0.73 | -3.32 | 1.69 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 4.19 | 3.81 | 18.16 | 14.94 | 16.83 | |
| Research and developement to revenue | 16.62 | 25.52 | 85.65 | -33.38 | 3.33 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 1.49 | 1.58 | 6.25 | 5.66 | 5.53 | |
| Graham number | 1.67 | 2.61 | 1.64 | 1.14 | 0.57 | |
| ROIC | -142.66 | 1.19 | 0.43 | -0.1 | 0.08 | |
| Return on tangible assets | -0.3 | -0.61 | -0.9 | 0.39 | -0.81 | |
| Graham Net | -0.42 | -0.74 | -0.53 | -0.8 | -0.43 | |
| Working capital | 54K | -27.63M | -50.51M | -45.09M | -48.27M | |
| Tangible asset value | -25.05M | -50.09M | -52.41M | -46.77M | -49.73M | |
| Net current asset value | -25.14M | -50.18M | -52.5M | -46.86M | -49.82M | |
| Invested capital | -1.01 | -0.51 | 0 | 0 | 0 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 46.29M | 52.27M | 55M | 46.93M | 39.46M | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0 | 0 | 0 | 0 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | 0.85 | 0.6 | 0.45 | -0.09 | 0.08 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
HGEN Frequently Asked Questions
What is Humanigen, Inc. stock symbol ?
Humanigen, Inc. is a US stock , located in Short hills of Nj and trading under the symbol HGEN
What is Humanigen, Inc. stock quote today ?
Humanigen, Inc. stock price is $0.0002 today.
Is Humanigen, Inc. stock public?
Yes, Humanigen, Inc. is a publicly traded company.
Company Profile
- Volume Average 341.85K
- Market Capitalization 23.82K
- Employee 6
- CEO Dr. Cameron Durrant M.D., MBA
- Headquarters Short Hills,NJ,US
- IPO Date 2013-01-31
-
Website
https://www.humanigen.com 
Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response called cytokine storm'. Lenzilumab is an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF). The company is developing lenzilumab as a treatment for cytokine storm associated with COVID-19 for which it has completed a Phase 3 study and is the focus of a Phase 2/3 study sponsored by the NIH. It is also developing lenzilumab, which is also being studied in conjunction with CD19-targeted CAR-T cell therapies, as well as exploring the effectiveness of lenzilumab in other inflammatory conditions, such as acute Graft versus Host Disease in patients undergoing allogeneic hematopoietic stem cell transplantation and in eosinophilic asthma, and rheumatoid arthritis. In addition, the company focuses on studying lenzilumab for patients with chronic myelomonocytic leukemia exhibiting RAS pathway mutations. Its pipeline also includes two other Humaneered monoclonal antibodies, ifabotuzumab, which binds to EphA3, and HGEN005, which targets EMR1. Ifabotuzumab has been evaluated in a Phase 1 study of glioblastoma multiforme that showed tumor specific targeting of all known tumor sites with no normal tissue uptake. HGEN005 is being explored as a treatment for a range of eosinophilic diseases, including eosinophilic leukemia as an optimized naked antibody and as the backbone for a novel CAR-T construct. Humanigen, Inc. was incorporated in 2000 and is headquartered in Short Hills, New Jersey.
